These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 2191570)
1. [Clinical studies on endocrine therapy of prostatic carcinoma (2): Prognosis of patients with prostatic carcinoma given endocrine therapy, and analyses of causes of death and side effects of endocrine therapy]. Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Oshima H; Takeuchi H; Yoshida O; Okada K; Saito Y Hinyokika Kiyo; 1990 Mar; 36(3):285-93. PubMed ID: 2191570 [TBL] [Abstract][Full Text] [Related]
2. [Clinical studies on endocrine therapy of prostatic carcinoma (1): Multivariate analyses of prognostic factors in patients with prostatic carcinoma given endocrine therapy]. Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Ohshima H; Takeuchi H; Yoshida O; Okada K; Saito Y Hinyokika Kiyo; 1990 Mar; 36(3):275-84. PubMed ID: 2191569 [TBL] [Abstract][Full Text] [Related]
3. [Clinical studies on endocrine therapy of prostatic carcinoma (3): Histopathological features of prostatic carcinoma and its prognosis]. Kumamoto Y; Tsukamoto T; Umehara T; Harada M; Shimazaki J; Fuse H; Oshima H; Takeuchi H; Yoshida O; Okada K Hinyokika Kiyo; 1990 Mar; 36(3):295-305. PubMed ID: 2191571 [TBL] [Abstract][Full Text] [Related]
4. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen]. Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527 [TBL] [Abstract][Full Text] [Related]
5. [Side effects of estrogen administration to prostatic cancer patients: clinical and statistical survey of 109 prostatic cancer cases of Kyoto University Hospital]. Oishi K; Arai Y; Takeuchi H; Yoshida O Hinyokika Kiyo; 1993 Jan; 39(1):23-8. PubMed ID: 8460581 [TBL] [Abstract][Full Text] [Related]
6. [Factors influencing prognosis of stage D2 prostatic cancer following endocrine therapy: comparison between short-term cancer death and long-term survival group]. Masai M; Akimoto S; Isaka S; Shimazaki J; Yatani R Hinyokika Kiyo; 1990 Jun; 36(6):667-71. PubMed ID: 1700585 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766 [TBL] [Abstract][Full Text] [Related]
8. [Prostatic carcinoma. I: Androgen dependency of prostatic carcinoma]. Shimazaki J; Fuse H; Akimoto S; Sumiya H; Akakura K; Ichikawa T Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):909-16. PubMed ID: 3389834 [TBL] [Abstract][Full Text] [Related]
9. "Just Another Statistic". Machtay M; Glatstein E Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105 [TBL] [Abstract][Full Text] [Related]
10. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. Jordan WP; Blackard CE; Byar DP South Med J; 1977 Dec; 70(12):1411-3. PubMed ID: 594790 [TBL] [Abstract][Full Text] [Related]
11. Current concepts in the management of prostatic cancer. Schröder FH Am J Clin Oncol; 1988; 11 Suppl 1():S1-5. PubMed ID: 3389335 [TBL] [Abstract][Full Text] [Related]
12. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer]. Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583 [TBL] [Abstract][Full Text] [Related]
13. [Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)]. Kondo I; Miura T; Fujii H; Harada M; Fukushima S; Kubota Y; Hosaka M Hinyokika Kiyo; 1996 Mar; 42(3):201-6. PubMed ID: 8619389 [TBL] [Abstract][Full Text] [Related]
14. [Progress of endocrine therapy for prostate cancer and results]. Kanetake H Gan To Kagaku Ryoho; 1996 Mar; 23(4):413-7. PubMed ID: 8678491 [TBL] [Abstract][Full Text] [Related]
15. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Hinotsu S; Akaza H; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M; Yamanaka H; Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423 [TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy of breast and prostate cancer. Manni A Endocrinol Metab Clin North Am; 1989 Jun; 18(2):569-92. PubMed ID: 2663486 [TBL] [Abstract][Full Text] [Related]
17. [Reevaluation and potential therapeutic effects of estrogen therapy to prostate cancer patients]. Kato M; Kase H; Okada K; Tohma T; Ishiwata D Nihon Rinsho; 1998 Aug; 56(8):2140-4. PubMed ID: 9750523 [TBL] [Abstract][Full Text] [Related]
18. [Five-year trend in new patients with prostatic carcinoma]. Moriyama N; Akaza H; Sugimoto M; Taniguci J; Hara M; Fukutani K; Kitamura T; Higashihara E; Kishi H; Umeda T Hinyokika Kiyo; 1988 Jun; 34(6):997-1001. PubMed ID: 3066215 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients. Grande M; Carlström K; Rozell BL; Stege R; Pousette A Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899 [TBL] [Abstract][Full Text] [Related]
20. [Trends of prostate cancer: comparison between 1986-90 and 1991-95 at Asahi General Hospital]. Tanaka M; Murakami S; Suzuki N; Oikawa T; Kinsui H; Hamano S; Shimazaki J Hinyokika Kiyo; 1998 Nov; 44(11):775-80. PubMed ID: 9893221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]